Affiliation:
1. School of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, China
2. Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng 252000, China
Abstract
Paxlovid®, a co-packaged medication comprised of separate tablets containing two active ingredients, nirmatrelvir (NRV) and ritonavir (RTV), exhibits good effectiveness against coronavirus disease 2019 (COVID-19). However, the size of the NRV/RTV tablets makes them difficult for some patients to swallow, especially the elderly and those with dysphagia. Therefore, an oral liquid formulation that can overcome this shortcoming and improve patient compliance is required. In this study, we developed a liquid formulation containing NRV and RTV by adopting strategies that used co-solvents and surfactants to enhance the solubility and inhibit possible recrystallization. The in vitro release results showed that NRV and RTV could be maintained at high concentrations in solution for a certain period in the investigated media. In vivo studies in rats showed that the oral bioavailability of NRV/RTV solution was significantly enhanced. Compared to Paxlovid® tablets, the AUC(0–t) of NRV and RTV increased by 6.1 and 3.8 times, respectively, while the Cmax increased by 5.5 times for both. Furthermore, the promoting effect of the absorption of RTV on the bioavailability of NRV was confirmed. Experiments with a beagle showed a similar trend. Stability studies were also conducted at 4 °C, 25 °C, and 40 °C for 90 days, indicating that the oral liquid formulation was physically and chemically stable. This study can be used as a valuable resource for developing and applying oral liquid NRV/RTV formulations in a clinical context.
Funder
National Science and Technology Major Project
Open Project of Shandong Collaborative Innovation Center for Antibody Drugs
Taishan Scholar Research Fund of Shandong Province of China
Reference54 articles.
1. World Health Organization (2022, October 05). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/.
2. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study;Chen;Lancet,2020
3. Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection;Khamis;J. Infect. Public Health,2021
4. U.S. Food and Drug Administration (2023, October 08). Paxlovid® (Nirmatrelvir Co-Packaged with Ritonavir) for the Treatment of Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) in Certain Adults and Pediatric Patients, Available online: https://www.fda.gov/media/155049/download.
5. Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations;Walsh;Int. J. Pharm.,2018